NiCu-silica nanoparticles as a potential drug delivery system
Source abstract
Abstract
Many groups have already investigated the use of NiCu magnetic nanoparticles (MNPs) as mediators for magnetic fluid hyperthermia, but we were the first to report the potential of NiCu MNPs as bimodal therapeutic systems, capable of simultaneous magnetic hyperthermia (MH) and targeted drug delivery. The superparamagnetic nanoparticles have a magnetic core, which enables their manipulation through an external magnetic field, a biocompatible layer, providing a surface for attachment of suitable receptors for targeting specific tissues, and a therapeutic load either incorporated inside the coating pores or hosted within internal cavities of the particles. In this study, we incorporated three model drugs with different pharmacological activity into superparamagnetic NixCu1−x nanoparticles. The superparamagnetic NixCu1−x nanoparticles were prepared using a sol–gel method, and exhibited a Curie temperature (TC) in the therapeutic range for use in MH. The nanoparticles were prepared in a silica matrix to avoid their agglomeration during thermal treatment and to provide suitable compartments for incorporation inside the pores. The release of the incorporated drugs paracetamol, bupivacaine hydrochloride, and pentoxifylline was studied using an in vitro release system, where UV–visible spectrophotometry (UV/Vis) was used for quantification of the released drug. The NixCu1−x nanoparticles were characterized using X-ray diffraction analysis, thermogravimetric analysis (TGA/SDTA), Fourier transform infrared spectroscopy, scanning electron microscopy, and magnetic measurements. Surface area and pore size were determined by using BET analysis. Finally, the biocompatibility of the samples was tested on human skin-derived fibroblasts.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Tartaj P, Morales MdP, Veintemillas-Verdaguer S, González-Carreño T, Carlos JS (2003) The preparation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys 36:R18210.1088/0022-3727/36/13/202 ↗
2. Dobson QAP, Connolly J, Jones SK (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 36:R16710.1088/0022-3727/36/13/201 ↗
3. Tartaj P, Morales MP, González-Carreño T, Veintemillas-Verdaguer S, Serna CJ (2005) Advances in magnetic nanoparticles for biotechnology applications. J Magn Magn Mater 290–291:28–34. Part 110.1016/j.jmmm.2004.11.155 ↗
4. Ban I, Stergar J, Maver U (2018) NiCu magnetic nanoparticles: review of synthesis methods, surface functionalization approaches, and biomedical applications. Nanotechnol Rev 7:18710.1515/ntrev-2017-0193 ↗
5. Cihoric N, Tsikkinis A, van Rhoon G, Crezee H, Aebersold DM, Bodis S, Beck M, Nadobny J, Budach V, Wust P, Ghadjar P (2015) Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry. Int J Hyperth 31:609–61410.3109/02656736.2015.1040471 ↗
6. Dobson J (2006) Magnetic nanoparticles for drug delivery. Drug Dev Res 67:55–6010.1002/ddr.20067 ↗
7. Sun C, Lee JS, Zhang M (2008) Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 60:1252–126510.1016/j.addr.2008.03.018 ↗
8. Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R, Hubalek J (2010) Magnetic nanoparticles and targeted drug delivering. Pharmacol Res 62:144–14910.1016/j.phrs.2010.01.014 ↗
9. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J (2007) Magnetic nanoparticles for drug delivery. Nano Today 2:22–3210.1016/S1748-0132(07)70084-1 ↗
10. McBain SC, Yiu HHP, Dobson J (2008) Magnetic nanoparticles for gene and drug delivery. Int J Nanomed 3:169–180
11. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H (2012) Nanoparticles as drug delivery systems. Pharmacol Rep 64:1020–103710.1016/S1734-1140(12)70901-5 ↗
12. Ferk G, Stergar J, Makovec D, Hamler A, Jagličić Z, Drofenik M, Ban I (2015) Synthesis and characterization of Ni–Cu alloy nanoparticles with a tunable Curie temperature. J Alloy Compd 648:53–5810.1016/j.jallcom.2015.06.067 ↗
13. Bajpai AK, Gupta R (2011) Magnetically mediated release of ciprofloxacin from polyvinyl alcohol based superparamagnetic nanocomposites. J Mater Sci Mater Med 22:357–36910.1007/s10856-010-4214-2 ↗
14. Munnier E, Cohen-Jonathan S, Linassier C, Douziech-Eyrolles L, Marchais H, Souce M, Herve K, Dubois P, Chourpa I (2008) Novel method of doxorubicin-SPION reversible association for magnetic drug targeting. Int J Pharm 363:170–17610.1016/j.ijpharm.2008.07.006 ↗
15. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS (2000) Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60:6641–6648
16. Lubbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dorken B, Herrmann F, Gurtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D (1996) Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56:4686–4693
17. Kayal S, Ramanujan RV (2010) Doxorubicin loaded PVA coated iron oxide nanoparticles for targeted drug delivery. Mater Sci Eng: C 30:484–49010.1016/j.msec.2010.01.006 ↗
18. Hałupka-Bryl M, Bednarowicz M, Dobosz B, Krzyminiewski R, Zalewski T, Wereszczyńska B, Nowaczyk G, Jarek M, Nagasaki Y (2015) Doxorubicin loaded PEG-b-poly(4-vinylbenzylphosphonate) coated magnetic iron oxide nanoparticles for targeted drug delivery. J Magn Magn Mater 384:320–32710.1016/j.jmmm.2015.02.078 ↗
19. Oka C, Ushimaru K, Horiishi N, Tsuge T, Kitamoto Y (2015) Core–shell composite particles composed of biodegradable polymer particles and magnetic iron oxide nanoparticles for targeted drug delivery. J Magn Magn Mater 381:278–28410.1016/j.jmmm.2015.01.005 ↗
20. Araújo-Barbosa S, Morales MA (2019) Nanoparticles of Ni1−xCux alloys for enhanced heating in magnetic hyperthermia. J Alloy Compd 787:935–94310.1016/j.jallcom.2019.02.148 ↗
21. Amrollahi P, Ataie A, Nozari A, Seyedjafari E, Shafiee A (2015) Cytotoxicity evaluation and magnetic characteristics of mechano-thermally synthesized CuNi nanoparticles for hyperthermia. J Mater Eng Perform 24:1220–122510.1007/s11665-015-1398-0 ↗
22. Ban I, Stergar J, Drofenik M, Ferk G, Makovec D (2011) Synthesis of copper–nickel nanoparticles prepared by mechanical milling for use in magnetic hyperthermia. J Magn Magn Mater 323:2254–225810.1016/j.jmmm.2011.04.004 ↗
23. Ferk G, Stergar J, Drofenik M, Makovec D, Hamler A, Jagličić Z, Ban I (2014) The synthesis and characterization of nickel–copper alloy nanoparticles with a narrow size distribution using sol–gel synthesis. Mater Lett 124:39–4210.1016/j.matlet.2014.03.030 ↗
24. Stergar J, Ferk G, Ban I, Drofenik M, Hamler A, Jagodič M, Makovec D (2013) The synthesis and characterization of copper–nickel alloy nanoparticles with a therapeutic Curie point using the microemulsion method. J Alloy Compd 576:220–22610.1016/j.jallcom.2013.04.130 ↗
25. Chatterjee J, Bettge M, Haik Y, Chen CJen (2005) Synthesis and characterization of polymer encapsulated Cu–Ni magnetic nanoparticles for hyperthermia applications. J Magn Magn Mater 293:303–30910.1016/j.jmmm.2005.02.024 ↗
26. Paulus JA, Parida GR, Tucker RD, Park JB (1997) Corrosion analysis of NiCu and PdCo thermal seed alloys used as interstitial hyperthermia implants. Biomaterials 18:1609–161410.1016/S0142-9612(97)00102-6 ↗
27. Bettge M, Chatterjee J, Haik Y (2004) Physically synthesized Ni-Cu nanoparticles for magnetic hyperthermia. Biomagn Res Technol 2:4–410.1186/1477-044X-2-4 ↗
28. Ahmed J, Ramanujachary KV, Lofland SE, Furiato A, Gupta G, Shivaprasad SM, Ganguli AK (2008) Bimetallic Cu–Ni nanoparticles of varying composition (CuNi3, CuNi, Cu3Ni). Colloids Surf A: Physicochemical Eng Asp 331:206–21210.1016/j.colsurfa.2008.08.007 ↗
29. Feng J, Zhang C-P (2006) Preparation of Cu–Ni alloy nanocrystallites in water-in-oil microemulsions. J Colloid Interface Sci 293:414–42010.1016/j.jcis.2005.06.071 ↗
30. Songping W, Jing N, Li J, Zhenou Z (2007) Preparation of ultra-fine copper–nickel bimetallic powders with hydrothermal–reduction method. Mater Chem Phys 105:71–7510.1016/j.matchemphys.2007.04.027 ↗
31. Mohamed Saeed GH, Radiman S, Gasaymeh SS, Lim HN, Huang NM (2010) Mild hydrothermal synthesis of Ni–Cu nanoparticles. J Nanomater 2010:510.1155/2010/184137 ↗
32. Foyet A, Hauser A, Schäfer W (2007) Double template electrochemical deposition and characterization of NiCo and NiCu alloys nanoparticles and nanofilms. J Solid State Electrochem 12:47–5510.1007/s10008-007-0332-2 ↗
33. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF (2013) The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 21:201–23210.1007/s10787-013-0172-x ↗
34. Bardsley H, Gristwood R, Baker H, Watson N, Nimmo W (1998) A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 46:245–24910.1046/j.1365-2125.1998.00775.x ↗
35. Schonharting MM, Schade UF (1989) The effect of pentoxifylline in septic shock-new pharmacologic aspects of an established drug. J Med 20:97–105
36. Dobson QAPaJCaSKJaJ (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 36:R16710.1088/0022-3727/36/13/201 ↗
37. Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–402110.1016/j.biomaterials.2004.10.012 ↗
38. Issa B, Obaidat IM, Albiss BA, Haik Y (2013) Magnetic nanoparticles: surface effects and properties related to biomedicine applications. Int J Mol Sci 14:21266–2130510.3390/ijms141121266 ↗
39. Stergar J, Ban I, Gradišnik L, Maver U (2018) Novel drug delivery system based on NiCu nanoparticles for targeting various cells. J Sol–Gel Sci Technol 88:57–6510.1007/s10971-017-4513-x ↗
40. Maver U, Xhanari K, Zizek M, Korte D, Gradisnik L, Franko M, Finsgar M (2018) A combination of interdisciplinary analytical tools for evaluation of multi-layered coatings on medical grade stainless steel for biomedical applications. Eur J Pharm Biopharm 128:230–24610.1016/j.ejpb.2018.05.002 ↗
41. Milojević M, Gradišnik L, Stergar J, Skelin Klemen M, Stožer A, Vesenjak M, Dobnik Dubrovski P, Maver T, Mohan T, Stana Kleinschek K, Maver U (2019) Development of multifunctional 3D printed bioscaffolds from polysaccharides and NiCu nanoparticles and their application. Appl Surf Sci 488:836–85210.1016/j.apsusc.2019.05.283 ↗
42. Sykuła-Zając A, Łodyga-Chruścińska E, Pałecz B, Dinnebier RE, Griesser UJ, Niederwanger V (2011) Thermal and X-ray analysis of racemic bupivacaine hydrochloride. J Therm Anal Calorim 105:1031–103610.1007/s10973-011-1425-9 ↗
43. Bavnhøj CG, Knopp MM, Madsen CM, Löbmann K (2019) The role interplay between mesoporous silica pore volume and surface area and their effect on drug loading capacity. Int J Pharm: X 1:100008
44. Refat MS, Mohamed GG, El-Sayed MY, Killa HMA, Fetooh H (2017) Spectroscopic and thermal degradation behavior of Mg(II), Ca(II), Ba(II) and Sr(II) complexes with paracetamol drug. Arab J Chem 10:S2376–S238710.1016/j.arabjc.2013.08.017 ↗
45. Martins ML, Eckert J, Jacobsen H, dos Santos EC, Ignazzi R, de Araujo DR, Bellissent-Funel M-C, Natali F, Marek Koza M, Matic A, de Paula E, Bordallo HN (2017) Raman and Infrared spectroscopies and X-ray diffraction data on bupivacaine and ropivacaine complexed with 2-hydroxypropyl−β−cyclodextrin. Data Brief 15:25–2910.1016/j.dib.2017.08.053 ↗
46. Rahim SA, Carter PA, Elkordy AA (2015) Design and evaluation of effervescent floating tablets based on hydroxyethyl cellulose and sodium alginate using pentoxifylline as a model drug. Drug Des Dev Ther 9:1843–1857
47. Maver U, Godec A, Bele M, Planinšek O, Gaberšček M, Srčič S, Jamnik J (2007) Novel hybrid silica xerogels for stabilization and controlled release of drug. Int J Pharmaceutics 330:164–17410.1016/j.ijpharm.2006.09.024 ↗
48. Godec A, Maver U, Bele M, Planinsek O, Srcic S, Gaberscek M, Jamnik J (2007) Vitrification from solution in restricted space: formation and stabilization of amorphous nifedipine in a nanoporous silica xerogel carrier. Int J Pharm 343:131–14010.1016/j.ijpharm.2007.05.022 ↗
49. Maver U, Žnidaršič A, Saboti D, Srčič S, Gaberšček M, Godec A, Planinšek O (2010) The relation between the interfacial contact and SiO2 coating efficiency and properties in the case of two clarithromycin polymorphs. Colloids Surf A: Physicochem Eng Asp 371:119–12510.1016/j.colsurfa.2010.09.016 ↗
50. Ukmar T, Maver U, Planinšek O, Pintar A, Kaučič V, Godec A, Gaberšček M (2012) Guest–host van der Waals interactions decisively affect the molecular transport in mesoporous media. J Mater Chem 22:1112–112010.1039/C1JM13493K ↗